Caribou Biosciences, Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Caribou Biosciences, Inc. (CRBU) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Notes
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2024-03-11
- Caribou Biosciences, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $0.00.
- Caribou Biosciences, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Caribou Biosciences, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $27.00K.
- Caribou Biosciences, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2020 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-11 | |
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2021-12-31 | $27.00K 10-K · filed 2023-03-09 | $0.00 10-K · filed 2022-03-21 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-21 | |
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |